Preclinical support for using psychedelics to treat alcohol use disorders
Focusing on female mice because they drink more alcohol than male mice, the researchers discovered that psilocin dampened the activity of these neurons following long-term alcohol exposure. This decrease in activity was associated with less alcohol drinking during drug exposure, though drinking was restored in later sessions. These observations also occurred in mice with less severe alcohol exposure, supporting clinical work showing that psychedelics may help improve issues with emotional processing and stress across a range of psychiatric disorders.
According to the researchers, these findings may shape interpretations of clinical studies on psychedelic treatments. Elaborating on their findings, says Herman, “It makes sense that dampening this neuron population reduces drinking because increased activity in these neurons is associated with alcohol use disorders. These neurons also play a role in depression and anxiety, which psychedelics are also showing promise at treating, so our work provides some mechanistic insight in those contexts, too.”
###
Please contact media@sfn.org for full-text PDF.
About JNeurosci
JNeurosci was launched in 1981 as a means to communicate the findings of the highest quality neuroscience research to the growing field. Today, the journal remains committed to publishing cutting-edge neuroscience that will have an immediate and lasting scientific impact, while responding to authors' changing publishing needs, representing breadth of the field and diversity in authorship.
About The Society for Neuroscience
The Society for Neuroscience is the world's largest organization of scientists and physicians devoted to understanding the brain and nervous system. The nonprofit organization, founded in 1969, now has nearly 35,000 members in more than 95 countries.
END